Instrument Inactif

Gouvernance Chromadex Corp OTC Bulletin Board

CDXC

US1710771007

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board
- ^USD	-

21/09	Niagen Bioscience annonce la publication d'une étude préclinique démontrant que CD38 est un moteur du déclin du NAD+ lié à l'âge et que la restauration par le nicotinamide riboside améliore l'issue des grossesses	CI
06/08	Niagen Bioscience, Inc. lance Tru Niagen sur Walmart.com, renforçant son accessibilité et diversifiant sa présence sur le marché du commerce électronique	CI

Comité Exécutif: Chromadex Corp

Dirigeant

Fonctions occupéesDepuis

Robert Fried

66 ans

Chief Executive Officer

01/06/2018

Mona Rosene

Chief Tech/Sci/R&D Officer

01/07/2020

Michiko Kelley

Sales & Marketing

Ozan Pamir

35 ans

Comptroller/Controller/Auditor	21/10/2024
Director of Finance/CFO	21/10/2024

Carlos Lopez

General Counsel

22/07/2024

James Lee

51 ans

Comptroller/Controller/Auditor

Andrew Shao

General Counsel

01/02/2020

Aron Erickson

Chief Tech/Sci/R&D Officer

01/09/2014

Valter Pinto

Investor Relations Contact

Composition du Conseil d'Administration: Chromadex Corp

Administrateur

ComitésDepuis

Frank Jaksch

57 ans

Chairman

22/06/2018

Hamed Shahbazi

51 ans

Audit Committee Chair	01/06/2020
Compensation Committee Chair	01/06/2020
Governance Committee	09/08/2022
Nominating Committee	09/08/2022
Compensation Committee	11/09/2025
HR Committee	27/02/2024
Audit Committee	11/09/2025
Governance Committee Chair	11/09/2025
Nominating Committee Chair	11/09/2025

Steven Rubin

65 ans

Governance Committee	01/02/2026
Nominating Committee	01/02/2026
Audit Committee Chair	01/02/2026
Compensation Committee Chair
Audit Committee	01/03/2018
Governance Committee Chair
Nominating Committee Chair
Compensation Committee	01/02/2026

Kristin Patrick

55 ans

Compensation Committee	01/11/2018
Governance Committee	12/03/2026
Nominating Committee	12/03/2026
Audit Committee	15/04/2022
Governance Committee Chair	15/04/2022
Nominating Committee Chair	15/04/2022

Wing Tak Yu

50 ans

Governance Committee	01/03/2018
Nominating Committee	01/03/2018

Ann Cohen

65 ans

Compensation Committee	15/04/2022
Audit Committee Chair

Gary Ng

54 ans

Compensation Committee

13/12/2021

Robert Fried

66 ans

Director/Board Member

09/07/2015

Anciens Dirigeants et Administrateurs: Chromadex Corp

Insider

Fonctions occupées

DepuisJusqu'au

Brianna Gerber

Comptroller/Controller/Auditor	-	12/07/2024
Director of Finance/CFO	11/08/2022	12/07/2024
Investor Relations Contact	-	12/07/2024

Kurt Gustafson

Director/Board Member	21/10/2016	16/06/2022
Independent Dir/Board Member	21/10/2016	16/06/2022

Stephen Block

Director/Board Member	01/10/2007	16/06/2022
Independent Dir/Board Member	01/10/2007	16/06/2022

Caroline Levy

Director/Board Member	01/12/2021	11/04/2022
Independent Dir/Board Member	01/12/2021	11/04/2022

Jeff Baxter

Director/Board Member	16/04/2015	04/04/2022
Independent Dir/Board Member	16/04/2015	04/04/2022

Alex Worsham

Public Communications Contact	01/09/2019	01/04/2022
Corporate Officer/Principal	01/08/2017	01/09/2019
Sales & Marketing	01/09/2019	-

Tsz Ho Lau

Director/Board Member	18/08/2017	01/11/2021
Independent Dir/Board Member	18/08/2017	01/11/2021

William Carter

Corporate Officer/Principal

01/09/2021

Fadi Karam

Sales & Marketing

19/04/2021

Mark J. Friedman

General Counsel	23/01/2018	12/03/2021
Corporate Secretary	23/01/2018	-

Lisa Harrington

General Counsel	01/12/2020	01/01/2021
Corporate Secretary	01/12/2020	01/01/2021

Frank M. Fazio

Sales & Marketing

01/11/2020

Matthew Roberts

Chief Tech/Sci/R&D Officer

06/11/2018

01/02/2020

Lisa Bratkovich

Sales & Marketing

04/06/2018

10/01/2020

Jordan A. Gropack

Human Resources Officer

01/04/2018

01/10/2019

Alberto Bottene

Sales & Marketing

06/08/2019

Megan Jordan

Public Communications Contact	06/08/2019	-
Sales & Marketing	10/01/2020	-

Amy Boileau

Chief Tech/Sci/R&D Officer

01/12/2016

01/01/2019

Will Black

Sales & Marketing

16/05/2016

01/01/2019

Troy Allen Rhonemus

Chief Operating Officer	06/03/2014	08/01/2018
Chief Tech/Sci/R&D Officer	21/01/2018	20/11/2018
Corporate Officer/Principal	08/01/2018	21/01/2018

Andrew L. Johnson

Investor Relations Contact

01/11/2014

01/11/2018

Stephen R. Allen

Director/Board Member	03/01/2014	25/02/2015
Chairman	25/02/2015	22/06/2018
Independent Dir/Board Member	03/01/2014	25/02/2015

Ben Shichman

Chief Tech/Sci/R&D Officer

01/04/2018

Thomas C. Varvaro

Comptroller/Controller/Auditor	01/01/2004	09/10/2017
Director/Board Member	01/03/2006	01/05/2010
Director of Finance/CFO	01/01/2004	09/10/2017
Corporate Secretary	01/03/2006	09/10/2017
Treasurer	24/12/2009	12/06/2012

Kevin Farr

Comptroller/Controller/Auditor	09/10/2017	-
Director/Board Member	-	-
Director of Finance/CFO	09/10/2017	11/08/2022

Reid Dabney

Director/Board Member	23/12/2009	19/08/2016
Independent Dir/Board Member	01/10/2007	19/08/2016

Ryan Dellinger

Corporate Officer/Principal

01/08/2016

William D. Smithburg

Director/Board Member

06/06/2016

20/06/2016

Hugh Dunkerley

Director/Board Member	23/12/2009	13/05/2016
Independent Dir/Board Member	01/10/2002	13/05/2016

Glenn Halpryn

Director/Board Member	26/05/2010	09/07/2015
Independent Dir/Board Member	20/05/2010	09/07/2015

Mark Germain

Director/Board Member	01/01/1999	20/04/2015
Founder	01/01/1999	20/04/2015
Independent Dir/Board Member	01/01/1999	20/04/2015

Michael Brauser

Director/Board Member	21/10/2011	26/10/2011
Chairman	26/10/2011	25/02/2015
Independent Dir/Board Member	14/10/2011	25/02/2015

Barry Honig

Director/Board Member	21/10/2011	26/10/2011
Chairman	26/10/2011	25/02/2015
Independent Dir/Board Member	14/10/2011	25/02/2015

Curtis Lockshin

Director/Board Member	30/03/2011	03/01/2014
Independent Dir/Board Member	30/03/2011	03/01/2014

Steve Allen

Director/Board Member

01/01/2014

Jeffrey Himmel

Director/Board Member	23/01/2012	11/06/2012
Investor Relations Contact	23/01/2012	11/06/2012
Public Communications Contact	23/01/2012	11/06/2012
President	23/01/2012	11/06/2012

Debra A. Heim

Chief Operating Officer

12/02/2012

11/06/2012

William Spengler

President

15/11/2010

17/02/2012

Ann Deren-Lewis

Corporate Officer/Principal

03/12/2013

Kevin M. Jaksch

Director/Board Member	20/05/2010	20/05/2010
Independent Dir/Board Member	20/05/2010	20/05/2010

Donald Sampson

Comptroller/Controller/Auditor	-	18/06/2008
Director of Finance/CFO	-	-
President	-	18/06/2008

Mark Jost

Chief Operating Officer	03/12/2013	01/03/2014
Corporate Officer/Principal	01/03/2014	-

Mark Morris

Corporate Officer/Principal	01/10/2015	-
Sales & Marketing	01/01/2007	-

Jason Campbell

Corporate Officer/Principal

Trent Crane

Sales & Marketing

Heather Van Blarcom

General Counsel	-	-
Corporate Secretary	-	-

Laura Carney

Investor Relations Contact	-	20/04/2015
Corporate Officer/Principal	-	-

Barbara M. Grant

Corporate Secretary	-	-
Treasurer	-	-

James D. McChesney

Chief Tech/Sci/R&D Officer

Dan Doan

Chief Operating Officer	24/12/2009	25/01/2012
Corporate Officer/Principal	25/01/2012	-

Tony Nguyen

Sales & Marketing

24/12/2009

Suhad Mughrabi

Corporate Officer/Principal

24/12/2009

David Kroes

Human Resources Officer

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	13
Femme	6

Dont comité exécutif

Homme	7
Femme	2

Dont Administrateurs

Homme	5
Femme	3

Niagen Bioscience, Inc. est une entreprise internationale spécialisée dans les sciences de la vie qui se consacre à la promotion d'un vieillissement en bonne santé. Ses divisions comprennent les produits de consommation, les ingrédients, les étalons de référence analytiques et les services, ainsi que les produits pharmaceutiques. La division Produits de consommation fournit directement aux consommateurs et aux distributeurs des compléments alimentaires finis contenant ses ingrédients exclusifs. Le segment des ingrédients développe et commercialise des technologies d'ingrédients exclusives, notamment le Niagen de qualité alimentaire et le Niagen de qualité pharmaceutique, et fournit ces ingrédients sous forme de matières premières aux fabricants de produits de consommation et aux installations de sous-traitance. Le segment des normes de référence analytiques et des services propose la fourniture de normes de référence phytochimiques ainsi que d'autres services de recherche et développement. Le segment pharmaceutique se concentre sur le développement pharmaceutique de son portefeuille de précurseurs de la nicotinamide adénine dinucléotide (NAD) en vue d'applications thérapeutiques potentielles dans le domaine des maladies rares.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société